Slide 1: Cover letter to stock exchanges: Investor Presentation
April 29, 2026 To The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited 25, P.J. Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No. C-1, G- Block, Mumbai 400 001 Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 Symbol: RPGL
Slide 2: Q4 and FY26 Performance
Q4 and FY26 Performance RPG Life Sciences Investors’ Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: Powered by Passion, Driven by Ethics
RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Domestic Formulations (DF) Immunosuppr
Slide 6: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies
RPG Life Sciences: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Textbook Brands Specialty Chronic Life Cycle Management Rheumatology (Existing Products) Trastuzumab Azathio
Slide 7: Consistent Market Outperformance
Consistent Market Outperformance Outperforming the market across all quarters; building momentum through the year Sustained Outperformance vs IPM FY 26 1.8X 1.6X 18.2 Full Year RPG Life Sciences grew 1.8x Outperformed IPM in all 4 17.2 faster than IPM in quarters. ~1.6X for the full 13.7 Q4 FY26 yea
Slide 8: Business Operations
Business Operations 7
Slide 9: Key strategic priorities for today's discussion
Driving a more purpose-led and performance-oriented organization 1 with stronger alignment across teams Scaling core brands with sustained double-digit growth like Naprosyn 2 progressing towards becoming a ₹100 cr+ brand Key strategic Agenda priorities for 3 Building a stronger specialty and chronic
Slide 10: Focusing on execution to drive growth & efficiency
Focusing on execution to drive growth & efficiency Driving improvement across cost, quality, growth & productivity 1 2 3 Strengthening Manufacturing & Driving Cost Efficiency Enhancing Quality & Compliance Capacity Implementing cost optimization Strengthening quality systems and Enhancing capacity a
Slide 11: People initiatives for building a happy performance focussed culture
People initiatives for building a happy performance focussed culture I Love My Work RPGLS Heroes Outperformance recognition I Cherish our Culture I am Growing We Skill. You Grow. RPGLS Parivar Competency building continuum Tyohar-Utsav Shrankhla Digital RPGLS family get- Akanksha together High Caree
Slide 12: Financial Performance
Financial Performance 11
Slide 13: Robust Q4 performance with 23.6% revenue growth
Robust Q4 performance with 23.6% revenue growth and 58.1% PAT (excl. exception) growth 23.6% 48.0% 58.1% Revenue from EBITDA PAT (excl. exceptional operations Q4 FY26 v/s Q4 FY25 items) Q4 FY26 v/s Q4 FY25 Q4 FY26 v/s Q4 FY25 Note: Q4 FY25 included ₹110 crore of exceptional items. 12
Slide 14: Q4 FY26 Financial Performance Update
Q4 FY26 Financial Performance Update: Revenue up by 23.6% with improved profitability (All figures in Rs. Crores) Revenue from Operations EBITDA & EBITDA Margin Figures in circle are Margins +23.6% +48.0% 176.9 45.2 143.1 30.6 25.6% 21.4% 17.5% Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 PBT & PBT Margin (exclu
Slide 15: FY26 v/s FY25: Financial Performance Update
FY26 v/s FY25: Financial Performance Update (All figures in Rs. Crores) Revenue from Operations EBITDA & EBITDA Margin Figures in circle are Margins 8.3% 707.5 172.3 172.7 653.4 26.4% 24.4% 17.5% FY25 FY26 FY25 FY26 PBT & PBT Margin (excluding exceptional items) PAT & PAT Margin (excluding exception
Slide 16: FY26: Business Segment-wise Performance Update
FY26: Business Segment-wise Performance Update All sales value in INR cr. Domestic Formulations contributed 68.9% to total sales in FY26 +13.7% • Continue to deliver market beating growth 483.5 Domestic 425.0 • New products contribution improving consistently on account of new launches in Business S
Slide 17: Long term rating reaffirmed at A+ and outlook retained as stable
RPG Life Sciences ICRA Rating Reaffirmation A- (FY19) to A(FY21) to A+ (FY24) Improvements recorded in ICRA Factors affecting rating Rating- April’25 affirmation • A robust capital structure and strong debt servicing indicators based on: o Healthy cash flows Long term rating reaffirmed o Company con
Slide 18: Business Strategy
Business Strategy 17
Slide 19: Domestic Formulations (DF) Business: Overview & Strategy
Domestic Formulations (DF) Business: Overview & Strategy Overview Leading Textbook Diverse Portfolio Innovation & Growth Specialist Reach Brands Operating across mass, New launches in Strong presence across key Azoran, Aldactone, mass-specialty, and biosimilars, chronic, and specialties (Cardio, Dia
Slide 20: International Formulations (IF) Business: Overview & Strategy
International Formulations (IF) Business: Overview & Strategy Overview Global Reach Specialist Leadership Trusted Partnerships Quality & Expansion Presence in regulated and Strong position in Impeccable supply track Preferred partner for high- emerging markets across immunosuppressants, with record
Slide 21: APIs Business: Overview & Strategy
APIs Business: Overview & Strategy Business Overview Niche API Focus Global Presence Strategic Integration Trusted Partnerships High-value, low-volume Presence across key geographies: Backward integration with Enduring relationships with APIs and mature, stable LATAM, Germany, China, South Internati
Slide 22: Infrastructure Capabilities & ESG Initiatives
Infrastructure Capabilities & ESG Initiatives 21
Slide 23: Key highlights from our manufacturing facilities
Key highlighting from our 3 manufacturing facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • Modernization and
Slide 24: Digital Initiatives: Manufacturing and Quality
Digital Initiatives: Manufacturing and Quality Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Operates Pumps & Scanner enables • Implementation of Utility Asset Chillers according • Safe, reliab
Slide 25: ESG: Initiatives identified post industry mapping; good progress
ESG: Initiatives identified post industry mapping; good progress Initiatives FY26 Update • Carbon emission reduction ↓41.2 % in (FY25); FY26 Target- 50%; Actual - 48.5 % (FY26) Environmental • Energy Efficiency: Energy Efficient pumps ; Leakages rectification of compressed air system; High Efficienc
Slide 26: Journey Ahead
Journey Ahead 25
Slide 27: RPGLS Journey Ahead: strategic pillars of action
RPGLS Journey Ahead: 7 strategic pillars of action Portfolio development and • Project underway to grow our immunosuppressant portfolio to 200+ crores 1 mega-brands building • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio • Focus on new geographies, new lau
Slide 28: Thank You
THANK YOU L RPG LIFE SCIENCES